Atara Biotherapeutics (ATRA) Competitors $11.59 -0.17 (-1.45%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. ORIC, BNTC, FDMT, INBX, CADL, LRMR, RCKT, AMRN, ALDX, and ALTShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Benitec Biopharma (BNTC), 4D Molecular Therapeutics (FDMT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), Larimar Therapeutics (LRMR), Rocket Pharmaceuticals (RCKT), Amarin (AMRN), Aldeyra Therapeutics (ALDX), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Its Competitors Oric Pharmaceuticals Benitec Biopharma 4D Molecular Therapeutics Inhibrx Biosciences Candel Therapeutics Larimar Therapeutics Rocket Pharmaceuticals Amarin Aldeyra Therapeutics Altimmune Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability. Is ORIC or ATRA more profitable? Atara Biotherapeutics has a net margin of 3.07% compared to Oric Pharmaceuticals' net margin of 0.00%. Atara Biotherapeutics' return on equity of -8.34% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.75% -47.09% Atara Biotherapeutics 3.07%-8.34%6.61% Do analysts rate ORIC or ATRA? Oric Pharmaceuticals currently has a consensus price target of $17.63, suggesting a potential upside of 82.74%. Atara Biotherapeutics has a consensus price target of $21.00, suggesting a potential upside of 81.19%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Atara Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more volatility and risk, ORIC or ATRA? Oric Pharmaceuticals has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Does the media refer more to ORIC or ATRA? In the previous week, Oric Pharmaceuticals had 14 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 24 mentions for Oric Pharmaceuticals and 10 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.58 beat Oric Pharmaceuticals' score of 0.20 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals hold more shares of ORIC or ATRA? 95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 6.8% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, ORIC or ATRA? Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.89-5.10Atara Biotherapeutics$188.67M0.43-$85.40M-$0.43-26.95 SummaryOric Pharmaceuticals and Atara Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.75M$3.11B$5.76B$9.59BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-27.0720.4730.4425.11Price / Sales0.43235.16391.4087.03Price / CashN/A42.3737.0358.50Price / Book-2.327.868.886.18Net Income-$85.40M-$54.72M$3.26B$265.56M7 Day Performance-1.11%0.74%0.47%-1.43%1 Month Performance0.78%4.90%3.66%-0.98%1 Year Performance59.86%8.47%27.89%18.83% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics4.6444 of 5 stars$11.59-1.4%$21.00+81.2%+63.8%$81.75M$188.67M-27.07330News CoveragePositive NewsInsider TradeAnalyst RevisionORICOric Pharmaceuticals4.7319 of 5 stars$9.90+2.5%$17.63+78.0%-3.5%$938.21MN/A-5.2480Short Interest ↓Analyst RevisionBNTCBenitec Biopharma1.5555 of 5 stars$12.71-2.3%$26.00+104.6%+44.4%$341.52M$80K-8.4220News CoverageFDMT4D Molecular Therapeutics2.086 of 5 stars$7.27+0.1%$30.40+318.2%-55.3%$339.06M$40K-2.06120INBXInhibrx Biosciences1.9484 of 5 stars$23.87+2.3%N/A+89.1%$337.95M$200K-2.26166Short Interest ↓CADLCandel Therapeutics2.6237 of 5 stars$5.96-2.1%$22.00+269.1%+5.9%$334.31M$120K-8.6460Earnings ReportLRMRLarimar Therapeutics2.2341 of 5 stars$3.90-2.7%$18.43+372.5%-51.7%$331.94MN/A-2.5030Earnings ReportAnalyst RevisionRCKTRocket Pharmaceuticals4.8123 of 5 stars$3.03-0.7%$16.33+439.1%-80.6%$329.11MN/A-1.21240Trending NewsAnalyst ForecastAMRNAmarin0.1921 of 5 stars$16.17+3.3%$12.00-25.8%+23.5%$324.07M$228.61M-4.41360ALDXAldeyra Therapeutics2.0482 of 5 stars$5.44+0.9%$9.50+74.6%+4.6%$322.84MN/A-6.4010ALTAltimmune3.2084 of 5 stars$3.56-1.9%$17.40+388.8%-49.1%$320.37M$20K-3.0250 Related Companies and Tools Related Companies ORIC Alternatives BNTC Alternatives FDMT Alternatives INBX Alternatives CADL Alternatives LRMR Alternatives RCKT Alternatives AMRN Alternatives ALDX Alternatives ALT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access